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What’s new? 
 Studies of the remission of Type 2 diabetes through dietary means in people with a recent
diagnosis have, to date, been conducted in predominantly white populations in the UK. 
 In a predominantly black Caribbean population with Type 2 diabetes, diet-induced mean
weight loss of 10 kg was associated with remission (fasting plasma glucose < 7.0 mmol/l) in 
60% of participants at 8 weeks, and 38% at 8 months. 
 Negative peer pressure in social situations was one of several challenges participants
reported. 
 Remission of Type 2 diabetes is possible in this population.
 Further support to achieve and maintain greater weight loss is desirable.
Abstract 
Aim In a high proportion of people with recently diagnosed Type 2 diabetes, a short (2–3-month) 
low-calorie diet is able to restore normal glucose and insulin metabolism. The aim of this study was to 
determine the feasibility of this approach in Barbados. 
Methods Twenty-five individuals with Type 2 diabetes diagnosed within past 6 years, not on insulin, 
BMI > 27 kg/m
2 
were recruited. Hypoglycaemic medication was stopped on commencement of the 8-
week liquid (760 calorie) diet. Insulin response was assessed in meal tests at baseline, 8 weeks and 
8 months. Semi-structured interviews, analysed thematically, explored participants’ experiences. 
‘Responders’ were those with fasting plasma glucose (FPG) < 7 mmol/l at 8 weeks. 
Results Ten men and 15 women (mean age 48, range 26–68 years) participated. Mean (SD) BMI was 
34.2 kg/m
2
 (6.0); FPG 9.2 mmol/l (2.2). Mean weight loss at 8 weeks and 8 months was 10.1 kg [95% 
confidence interval (CI) 8.1, 12.0] and 8.2 kg (95% CI 5.8, 10.6); FPG was lower by 2.2 mmol/l
 
(95% 
CI 1.2, 3.2) and 1.7 mmol/l (95% CI 0.8, 2.7) respectively. Nine of 11 (82%) of those who lost 
≥ 10 kg were ‘responders’ compared with 6 of 14 (43%) who lost < 10 kg (P = 0.048). The 30-min 
insulin increment was higher in responders at baseline and follow-up (P ≤ 0.01). A food culture based 
on starchy foods and pressures to eat large amounts at social events were among the challenges 
identified by participants. 
Conclusions The feasibility of this approach to weight loss and diabetes remission in a predominantly 
black population in Barbados was demonstrated. 
<H1>Introduction 
The Caribbean population, predominantly of African origin, has overall rates of Type 2 diabetes 
among the highest in the world [1,2]. In Barbados, the prevalence of diabetes in adults aged 25 years 
and over was 18.7% (21.0% in women, 15.9% in men) in 2012; with an obesity prevalence of 33.8% 
(43.4% women; 23.4% men) [3]. 
Historically, Type 2 diabetes has been regarded as a lifelong, steadily progressive disease [4,5]. 
However, recent understanding changes this. It is caused by excess accumulation of fat in the liver 
and pancreas in susceptible individuals, causing failure of control of hepatic glucose production in the 
liver and loss of insulin secretory capacity in the pancreas [6–8]. The former remains completely 
reversible, and the latter is reversible in a high proportion of people during the first 6 years after 
diagnosis. In the weight management for remission of Type 2 diabetes trial (DiRECT), remission was 
achieved in 46% of participants in the intervention group (compared with 4% in the control group). 
Weight loss was achieved through a low-calorie liquid diet, and remission success rates were 
associated with the degree of weight loss, being 73% in those who lost > 10 kg at 12 months [9] and 
71% at 24 months [10]. 
The DiRECT study and associated proof of concept work were conducted in the England and 
Scotland, and < 2% of participants were of non-white ethnicity [7,9,11]. Successful application of this 
approach in populations and countries with different cultures and food systems cannot be assumed. 
Neither should it be assumed that the underlying physiology and metabolic responses to weight loss 
are the same in ethnically distinct populations [12]. The aim of this study was to examine, in people 
with Type 2 diabetes in Barbados, the feasibility and metabolic outcomes of the approach employed 
in the UK to bringing about remission of Type 2 diabetes. 
<H1>Participants and methods 
The overall design of this 8-month feasibility study followed that of similar work conducted in the 
UK [7,11] (Fig. 1). The study received ethical approval from the University of the West Indies 
Institutional Review Board, and from the Ministry of Health of the Government of Barbados. 
<H2>Study participants 
Twenty-five participants with Type 2 diabetes were recruited through a combination of publicity and 
contacts with local government and private healthcare providers. Participants had to be residents of 
Barbados with the following characteristics: aged 20–69 years; diagnosed with Type 2 diabetes 
(following World Health Organization criteria [13]) for 6 years or less; and with a BMI > 27 kg/m
2
. 
Exclusion criteria were: current insulin use; HbA1c > 12%; substance abuse; known cancer; 
myocardial infarction within the past 6 months; learning difficulties; current treatment with anti-
obesity drugs; diagnosed eating disorder/purging; pregnant/considering pregnancy; evidence of liver 
disease (including liver enzymes more than three times above normal values) or renal disease 
(creatinine of > 150 µmol/l); and persons who have required hospitalization for depression or are on 
antipsychotic drugs. 
<H2>Intervention 
The intervention was delivered by a family practitioner (KB), following a detailed study protocol that 
included how to provide support to participants to address challenges in adhering to the dietary 
guidance. Participants were encouraged to phone KB between visits should they need advice. 
Participants stopped any glucose-lowering medication on the day of starting the liquid diet (time 0). 
The liquid diet was supplied at no cost to participants and comprised four shakes per day, each shake 
containing 190 calories, 23 g carbohydrate, 10 g protein and 7 g fat. Participants were encouraged to 
consume 3 l of water, and three to four portions of high fibre low-carbohydrate vegetables per day. 
They were given a specially prepared recipe book for local low-carbohydrate vegetables. After 8 
weeks on the liquid diet they transitioned over a 4-week period to a solid diet, with support and 
guidance from a local dietitian on eating healthily and taking regular exercise. Remission of diabetes 
was defined as achieving a fasting plasma glucose (FPG) < 7.0 mmol/l [11,14]. 
<H2>Data collection 
Participants were seen weekly during the liquid diet phase, and monthly thereafter (Fig. 1). At each 
visit, weight, waist circumference, blood pressure and fasting glucose were measured following 
standard protocols. Height was measured at the first visit using a Seca 217 stadiometer. Weight was 
measured on a Seca 813 digital scale, waist and hip circumferences were measured twice, with a third 
measurement being taken if they differed by > 0.5 cm, and the mean of the two closest measurements 
used in analysis. Blood pressure was taken after the participant had been seated for at least 15 min. It 
was measured three times, at 3-min intervals, in the right arm using an Omron 705 CP digital monitor 
and an appropriate size cuff. The mean of the second and third measurements were used in analysis. 
Fasting glucose was measured on capillary blood using a Hemocue 201 RT analyser, with results 
given in plasma equivalent values. 
Participants underwent three standard meal tests, each consisting of two wholegrain biscuits 
(Weetabix), 200 ml semi-skimmed milk, 200 ml orange juice, a white bread roll, 20 g grape jam, and 
10 g margarine (equating to 575 calories, 72% carbohydrate, 15% protein, 13% fat). Venous blood 
samples were taken when the participant was fasting and then at 10, 20, 30, 60, 90 and 120 min after 
the meal. At each time point, blood was taken for the measurement of glucose, and serum was stored 
at −80 C for the subsequent measurement of C-peptide, insulin and non-esterified fatty acids 
(NEFA). Serum insulin was measured using the human insulin ELISA (EZHI-14K; Millipore, USA), 
C-peptide using the human C-peptide ELISA (EZHCP-20K; Millipore) and NEFA by NEFA-HR(2) 
(Wako Diagnostics, USA). In addition, the following were measured for the fasting sample: HbA1c 
(Bayer DCA 2000+ analyser; Bayer Healthcare LLC, USA), total cholesterol, HDL cholesterol, 
triglycerides, calculated LDL cholesterol and alanine aminotransferase (ALT) (Roche Reflotron plus 
analyser; Roche Diagnostics GmbH, Germany). HbA1c values were measured in NGSP units (%) and 
converted to IFCC ( mmol/mol) units using the Master Equation [15]. 
<H2>-Cell function 
-Cell function was assessed using the insulinogenic index [16], using the data from the meal tests, 
i.e. increment in insulin secretion between 30 min and baseline, divided by the equivalent increment 
in glucose. Assay results were available to calculate the insulinogenic index in 12 of 15 responders 
and 10 of 10 non-responders at baseline; 14 of 15 and 7 of 10 respectively at 8 weeks; and 15 of 15 
and 9 of 10 respectively at 8 months. 
<H2>Sample size and statistical analysis 
The sample size of 25 was based on the experience of the study in Newcastle, UK [7], which 
demonstrated significant changes with a sample size of 11. It was estimated that 25, allowing for 
attrition, would provide adequate power for meaningful before and after analyses. For example, with 
20 participants it is possible to demonstrate a 4 kg weight difference before vs. after, at P < 0.05 and 
with 90% power. In the Newcastle study, the mean weight loss was 15 kg. For fasting glucose, 20 
participants would enable a difference 1.1 mmol/l to be detected. Similar considerations apply to other 
measures. 
Data were analysed using STATA statistical software. Differences in continuous variables between 
baseline and follow-up were computed with paired t-tests. Independent t-tests were used to explore 
differences in continuous variables between ‘responders’ (fasting glucose, off medication, < 7 mmol/l 
by the end of 8 week diet phase) and ‘non-responders’ The Kruskal–Wallace test was used to compare 
insulin responses between these groups. The ‘cs’ command in STATA was used to calculate risk 
ratios. A 5% significance level was used and given the exploratory nature of these analyses no 
allowance was made for multiplicity of statistical tests. 
<H2>Qualitative data collection and analysis 
Individual semi-structured in-depth interviews were conducted with participants at three time points: 
baseline, end of the liquid diet phase (8 weeks) and end of the study (8 months). The interviews aimed 
to understand the experiences of participants, including the challenges they faced and the strategies 
they used to deal with them. All interviews with the exception of one were audio-taped and 
transcribed verbatim. Detailed notes were taken for the participant not wanting to be recorded. 
Interviews were analysed using ATLAS.ti v7 qualitative software (ATLAS.ti Scientific Software 
Development GmbH, Berlin Germany) and data were coded and then reviewed to extract any 
emerging themes. 
<H1>Results 
Twenty-five participants provided data at baseline, 8 weeks and 5 months. One participant failed to 
return for assessment at 8 months despite repeated attempts to encourage them to do so. Therefore, at 
8 months data were provided by 24 participants. 
<H2>Baseline clinical and metabolic characteristics 
Mean BMI was 34.2 kg/m
2
 (SD 6.0), age 48 (10) years, 60% were women and 88% classified 
themselves as black ethnicity, 8% as mixed, 4% as white. All males and 80% of females were taking 
oral hypoglycaemic agents. The mean duration of diagnosed diabetes reflected the selection criteria, 
3.0 (2.1) years. Details are shown in Table 1. 
Mean FPG and HbA1c were 9.2 (2.2) mmol/l and 65 mmol/mol (19) [8.1% (1.7)] respectively, and 
were similar in men and women. Mean plasma ALT was within the normal range and was higher in 
men than women (difference 10.8 U/l, 95% CI 2.0, 19.6) (Table 1). 
<H2>Effect of intervention on weight and metabolic parameters 
During the 8-week low-calorie diet phase, mean weight fell by 10.1 kg (95% CI 8.1, 12.0) (Table 2). 
The range of weight loss was 1.5 to 20.8 kg. Eleven  of 25 (44%) people lost > 10 kg and 4 of 25 
(16%) lost > 15 kg. Mean BMI fell by 3.4 kg/m
2 
(95% CI 2.9, 4.0), and mean waist circumference 
reduced by 10.9 cm (95% CI 9.3, 12.5). Between the end of the low-calorie diet and month 8, mean 
weight increased by 1.8 kg (95% CI −0.3, 3.9; P = 0.09). On average, men lost more weight than 
women; 11.7% of their baseline body weight by 8 weeks compared with 8.6% in women (95% CI on 
difference: 0.8, 5.4; P = 0.011). 
Following withdrawal of all hypoglycaemic agents and commencement of the low-calorie diet, FPG 
decreased by a mean of 1.5 mmol/l
 
(95% CI 0.5, 2.5) by week 2, 2.0 mmol/l (95% CI 1.1, 3.0) by 
week 3, and 2.2 mmol/l (95% CI 1.2, 3.2) by week 8. Thus, mean fasting glucose at week 8 was 
7.0 mmol/l (SD 1.4). At week 8, 60% (15/25) of the group achieved FPG < 7 mmol/l, and of those 
who lost > 10 kg, 82% (9 of 11) achieved FPG < 7.0 mmol/l. Between week 8 and the end of follow-
up, mean fasting glucose increased by 0.6 mmol/l (95% CI −0.04, 1.15; P = 0.07). Six months after 
the end of the low-calorie diet phase, 9 of 24 participants (37.5%) who were followed up had a FPG < 
7.0 mmol/l. 
The decrease in mean HbA1c was statistically significantly between baseline and week 8 [9 mmol/mol 
(95% CI 4, 15); 0.9% (95% CI 0.3, 1.4)]. It increased between week 8 and the end of the follow-up 
such that the mean decrease at month 8 compared with baseline was 7 mmol/mol (95% CI −4, 18; P = 
0.19) [0.6% (95% CI −0.3, 1.6]. 
There was evidence of improvement in both triglycerides and HDL cholesterol levels. Compared with 
baseline, mean triglycerides showed a statistically significant decrease at week 8 (0.23 mmol/l, 95% 
CI 0.05, 0.41), and HDL cholesterol showed a statistically significant increase at the end of the 
follow-up period (0.17 mmol/l, 95% CI 0.01, 0.32). Fasting plasma NEFA did not change from 
baseline to 8 weeks (1.04  0.14 and 1.17  0.18 mmol/l) but fell to 0.68  0.12 mmol/l (P < 0.01 
compared with baseline) by 8 months. The post-meal suppression of plasma NEFA did not change 
during the study (0.56  0.13, 0.73  0.13 and 0.47  0.23 mmol/l respectively). 
<H2>Characteristics of responders vs. non-responders 
Selected baseline characteristics of responders and non-responders are compared in Table 3. 
Responders and non-responders had a comparable age and duration of diabetes. A higher proportion 
of men were responders (8 of 10) than women (7 of 15), giving a relative risk of 1.7 in favour men but 
with a wide confidence interval (95% CI 0.9 to 3.2; P = 0.10). Mean baseline weight was 6.2 kg 
higher in responders, largely reflecting that mean baseline weight was 15 kg higher in men (Table 1). 
Baseline fasting glucose and HbA1c were similar in responders and non-responders. All three 
participants who self-assigned their ethnicity as either white (1) or mixed (2) were responders, 
compared with 12 of 22 (55%) who self-assigned their ethnicity as black (P = 0.32). 
Absolute and percentage mean weight loss at week 8 was slightly higher in responders vs. non-
responders, being 10.7 vs. 9.2 kg and 10.1% vs. 9.4 % respectively, but neither group difference was 
statistically significant (Table 3). Nine of 11 (82%) of those who lost ≥ 10 kg responded, compared 
with 6  of 14 (42.9%) who lost < 10 kg, risk ratio 1.9 (95% CI 1.0 to 3.7; P = 0.048). 
In responders, between baseline and week 8, fasting glucose fell by 3.2 mmol/l (95% CI 2.4, 4.5), 
compared with 0.8 mmol/l (95% CI −0.5, 2.1) in non-responders. There was no statistically 
significant change in fasting insulin in either group (P ≥ 0.2) or in ALT (P ≥ 0.3). A fall of borderline 
statistical significance was seen in mean triglyceride levels in the responders (0.27 mmol/l, 95% CI 0, 
0.54; P = 0.053) but not in the non-responders (0.18 mmol/l, 95% CI −0.07, 0.42; P = 0.14). 
There was no significant change in 0 to 30-min insulin increment between baseline and week 8 in 
either responders or non-responders (P ≥ 0.6), nor in the 0 to 30-min C-peptide increment (P > 0.1). 
<H2>Response to standard meal test 
For the group as a whole, there was a marked improvement in meal tolerance after the weight loss 
period (Fig. 2). In addition to fasting glucose falling from 9.2 to 7.0 mmol/l (95% CI on the decrease: 
1.2 to 3.2) between baseline and week 8, 60-min glucose fell from 13.3 to 10.4 mmol/l (95% CI 1.5 to 
4.2) and 120-min glucose from 13.5 to 10.8 mmol/l (95% CI 0.9 to 4.5). At 8 months, mean fasting 
[7.5 mmol/l (SD 0.3)], 60-min [11.0 (0.6) mmol/l] and 120-min [10.5 (0.7) mmol/l] glucose were not 
significantly different from the 8 week values, and remained significantly lower (P < 0.01) than 
baseline values. 
In the responders (n = 15), there was a significant increase in fasting plasma glucose (P = 0.001), but 
no significant change at 60 or 120 min during the meal test, between week 8 and 8 months (fasting 
+1.1 mmol/l, 95% CI 0.5 to 1.7; 60 min +0.8 mmol/l, 95% CI −0.1 to 1.6 and 120 min +0.1 mmol/l, 
95% CI −1.4 to 1.5). In the non-responders there was no statistically significant change between 
baseline and 8 weeks (fasting +0.8 mmol/l, 60 min +1.6 mmol/l, and 120 min +1.1 mmol/l). Between 
8 weeks and 8 months no further change occurred. 
The 30-min increment in plasma insulin was statistically significantly greater at baseline in the 
responder group (70.2 vs. 32.0 pmol/l; difference 38.2 pmol, 95% CI 1.4 to 75.1). This difference 
persisted at 8 weeks (75.3 vs. 29.1 pmol/l; difference 46.2 pmol/l, 95% CI 14.6 to 77.9) and at 8 
months (72.4 vs. 31.2 pmol/l; difference 41.2 pmol/l, 95% CI 8.0 to 74.4). The 30-min plasma C-
peptide response was not statistically significantly higher in responders at baseline but was 
significantly higher in the responders at 8 weeks (3.7 vs. 1.5; difference 2.2, 95% CI 0.9 to 3.5) and at 
8 months (3.4 vs. 1.3; difference 2.2, 95% CI 0.6 to 3.8). 
The insulinogenic index was higher in responders than in non-responders at all meal test time points 
(Table 4), although this difference was only statistically significant at month 8 (P = 0.031). 
Limiting the all the above analyses comparing responders to non-responders to the 22 black 
participants made only one difference of note to statistical significance. Six of eight (75%) who lost 
≥ 10 kg responded compared with 6 of 14 (43%) who lost < 10 kg, risk ratio 1.8 (95% CI 0.8, 3.8; 
P = 0.15). 
<H2>Participants’ experiences 
<H3>Structure of the low-calorie phase 
At baseline, many participants were concerned that the low-calorie phase of the intervention would be 
the most difficult. They were surprised to realize that they were able to handle the low-calorie phase 
more easily than initially perceived and some reported having more energy when interviewed at 8 
weeks. What most participants appreciated was the rigidity of the meal plan, which had very specific 
guidance on what they could or could not eat. In fact, most found the transition from the low-calorie 
phase to eating ‘regular’ foods the hardest as they attempted to navigate food choices. 
<H3>Food environment and culture 
The food environment proved to be a particularly difficult challenge due to temptations to consume 
foods not allowed during the intervention. For example, at social events it was expected that you 
would eat a lot of food, and if participants did not, they faced interrogation by peers. Additionally, 
cultural expectations dictate the acceptance of food that is offered to you: ‘… you can’t go in people’s 
house and not take what they offer you, they feel that you think what they have is not good enough’ 
(Phase 1, woman), which leads to having to explain in detail why participants could not accept what 
was offered. 
An associated challenge of the food environment was the availability and accessibility of healthy 
options such as fruit and vegetables. Culturally, Barbadians eat starchy and carbohydrate-heavy 
meals; it is not uncommon to see plates having a protein with two starches and a small amount of 
vegetables, so finding options when eating out was challenging, coupled with the higher cost of 
healthier foods compared to unhealthy foods. 
<H3>Acceptability of rapid weight loss 
Although rapid weight loss was a main goal of the intervention, the quick drop in weight loss was 
perceived in a positive light for women, but more negatively in men: ‘… it’s sad to hear things “man 
you looking small, you looking bony. What wrong with you?”. So, you just have to be strong 
mentally and laugh and say “look nothing aint really wrong”. “But why you look so?” You know 
people say “man you look bad, something wrong with you…”’ (Phase 2, man). 
This perception that something may be wrong with men who were losing weight rapidly changed how 
some men continued to progress in the study as they were more likely to modify the intervention plan 
as to not lose too much weight too quickly, whereas for women the positive reinforcement spurred 
them on to continue the intervention. 
<H3>Importance of social support 
The main facilitator of success in following the intervention and losing weight that was identified in 
the qualitative analysis is social support. Those participants having a diverse network of informal 
support systems made up of family members, close friends, co-workers and other participants, as well 
as formal support systems including the project staff and their primary doctors, had least difficulty in 
following the intervention. What appeared key for many was support received from close family 
members, many of whom changed their dietary behaviours at the same time. However, some 
participants who did less well reported very different experiences, including being ridiculed at times 
by family members for their new food choices. 
<H1>Discussion 
This study demonstrates that non-diabetic levels of glucose control can be restored by dietary means 
in Barbadian people with Type 2 diabetes. At the end of the 8-week liquid diet, of those losing 
> 10 kg in weight, 82% (9 of 11) returned to non-diabetic levels of blood glucose control (FPG < 
7 mmol/l). In the whole group, 38% had FPG < 7.0 mmol/l at the end of the study (8 months). The 
weight loss achieved in the whole group was substantial although less than that obtained by similar 
methods in studies elsewhere [7,17]. Individuals who achieved non-diabetic blood glucose control 
were characterized at baseline by having better preserved -cell function as indicated by a greater 
early insulin response to the standard test meal. 
The definition of remission of diabetes used in this study is consistent with previous studies 
(achieving a non-diabetic level of HbA1c or FPG after weight loss and off all hypoglycaemic agents) 
[9,11]. The threshold to diagnose diabetes remains that agreed by the American Diabetes Association 
and the World Health Organization (2002), as FPG ≥ 7.0 mmol/l [or subsequently, HbA1c 
≥ 48 mmol/mol (≥ 6.5%)]. In clinical practice, confirmation by a second test at least 2 months later is 
wise [14]. It is important to recognize that following weight loss, maintenance of a non-diabetic levels 
of FPG is associated with profound benefits in 10-year cardiovascular risk (QRISK® 23% to 7%) 
[8,11]. The state of ‘post diabetes’ is profoundly different to pre-diabetes in weight, plasma lipids and 
blood pressure, and even though plasma glucose levels may be above the defined normal range it is 
likely that this will impinge little upon their long-term health. Long-term follow-up after bariatric 
surgery demonstrates the low cardiovascular event rate consistent with the prognostic scores [18]. In 
other populations, HbA1c is usually used to define overall degree of glucose control. However, we 
have previously demonstrated that HbA1c tends to be higher in the Barbadian population for any given 
level of FPG giving a substantially higher prevalence of Type 2 diabetes than fasting glucose [19]. 
Similar findings have been reported in African Americans compared with white Americans [20–22]. 
The reasons for these differences are unclear and require further investigation, with hypotheses 
including that there are differences by ethnic group in the susceptibility to glycation of haemoglobin 
or that differences in underlying mean glucose concentrations are higher than reflected by fasting 
levels [23,24]. Given these uncertainties, in this study we have used FPG to define categories of 
glycaemic control. 
It is notable that both plasma lipids (total and LDL cholesterol, and triglyceride) and blood pressure 
are lower than in comparable white European origin populations with Type 2 diabetes [7,8,11]. 
Nonetheless macrovascular disease is common, with mortality rates from ischaemic heart disease and 
stroke in Barbados exceeding those in North America [25]. It may be that susceptibility to these 
factors is greater for any given measured level of exposure. This raises questions about the 
aetiological basis of Type 2 diabetes in the Barbadian population. For any given degree of adiposity, 
both liver and pancreas fat levels are lower in black populations [26]. This is reflected in the ALT 
levels observed in this study in comparison with our previous studies in largely white European origin 
groups [7,8,11]. Given the similarity of glycaemic response to weight loss, it appears likely that there 
are different levels of susceptibility to excess intra-organ triglyceride such that an increase from a 
lower baseline might be observed during the development of Type 2 diabetes in Afro-Caribbean 
populations. Direct study of liver and pancreas fat content is required in future studies of diabetes 
remission. 
As noted above, mean weight loss in this study (10 kg) was less than that achieved in similar studies 
in the UK (15 kg). The results from the in-depth interviews with participants provide insight into the 
challenges they faced. Navigating social expectations around food consumption was a particular 
challenge. This included the fact that it is seen as normal to ‘load up’ one’s plate and not doing so was 
to leave oneself open to unwelcome questions. Even if participants wished to substitute starchy 
carbohydrates with vegetables, these typically were unavailable or available in only small quantities. 
This lack of availability at least in part the high price of fruit and vegetables in Barbados [27] and the 
fact that only 10% of the general population report eating five or more portions per day [3]. 
During the low-calorie diet phase, men lost significantly more weight than women and had a higher 
(non-significant) rate of diabetes remission. Data from the participant interviews suggest that overall 
men received greater support from close family members. In a society in which traditional gender 
roles around food preparation persist, men tended to be supported by a partner preparing their food, 
whereas women were more often in the position of preparing food for other family members while in 
parallel trying to follow the study diet. 
This study has several limitations. It was a small non-randomized study to assess the feasibility in 
Barbados of an intervention found to be effective in the DiRECT trial [9]. The small numbers 
preclude meaningful subgroup analyses. Given the exploratory nature of the study the possibility of 
type 1 error is acknowledged. Our current follow-up of participants is to 8 months from baseline. 
Further follow-up will provide critical information on the potential longer term impacts of the 
intervention. 
In conclusion, remission of Type 2 diabetes is possible in Barbados. The underlying biology of the 
condition in this predominantly black population appears to be similar to that demonstrated in largely 
white European origin populations, although we acknowledge the desirability of further work to 
investigate the relationships between glucose metabolism and intrahepatic and intrapancreatic fat. The 
qualitative findings identified the serious challenges faced by participants of adhering to the low-
calorie diet and subsequently maintaining weight loss in what is a highly obesogenic environment, 
where two in three adults are overweight or obese and one in five has diabetes [3]. Our findings 
highlight the importance of social support and self-efficacy in navigating this environment and can 
guide improvements in the design of the intervention. However, major changes to the broader food 
environment in Barbados are likely to be necessary if this approach to diabetes remission is to be 
widely and successfully implemented. 
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FIGURE 1 Overview of the study design, showing low-calorie diet (LCD), transition (T) and maintenance 
phases. 
FIGURE 2 Change in response to the standard meal at baseline, after 8-week low-calorie diet and after 
8 months’ follow-up.  
Table 1 Baseline characteristics of the study population 
Characteristic Men (N = 10) Women (N = 15) All (N = 25) 
Age, years 51 (12) 46 (9) 48 (10) 
Ethnicity, % 
Black 80 93 88 
White 0 7 4 
Mixed 20 0 8 
Diabetes treatment, % 
Diet only 0 20 12 
Oral medication 100 80 88 
Time since diagnosis, years 3.0 (1.8) 3.1 (2.3) 3.0 (2.1) 
Weight, kg 107.7 (22.3) 92.3 (17.6) 98.5 (20.7) 
Height, cm 177.7 (8.9) 164.0 (5.6) 169.5 (9.7) 
BMI, kg/m
2
 33.9 (5.5) 34.4 (6.6) 34.2 (6.0) 
Waist circumference, cm 110.4 (14.7) 102.0 (15.1) 105.4 (15.2) 
Fasting plasma glucose, mmol/l 9.2 (2.2) 9.3 (2.2) 9.2 (2.2) 
HbA1c, mmol/mol 64 (21) 66 (17) 65 (19) 
HbA1c, % 8.0 (1.9) 8.2 (1.6) 8.1 (1.7) 
Alanine aminotransferase, U/l 27.2 (14.4) 16.4 (6.7) 20.7 (11.5) 
Total cholesterol, mmol/l 3.7 (0.8) 4.3 (0.7) 4.0 (0.8) 
HDL cholesterol, mmol/l 0.77 (0.24) 0.86 (0.28) 0.82 (0.26) 
LDL cholesterol, mmol/l 2.4 (0.8) 2.9 (0.7) 2.7 (0.8) 
Triglycerides, mmol/l 1.30 (0.44) 1.04 (0.41) 1.15 (0.43) 
Statin therapy, % 40 13 24 
Systolic BP, mmHg 134.1 (15.6) 125.5 (11.3) 129.1 (13.7) 
Diastolic BP, mmHg 79.3 (8.0) 79.7 (7.6) 79.5 (7.6) 
On treatment for raised BP, % 60 40 48 
Data are given as mean (SD) unless specified otherwise. 
Table 2 Change in selected characteristics between baseline and follow-up 
8 weeks 5 months 8 months 
Characteristic N = 25 N = 25 N = 24 
Weight, kg 10.1 (8.1, 12.0)§ 9.9 (7.9, 12.0)§ 8.2 (5.8, 10.6)§ 
BMI, kg/m
2
 3.4 (2.9, 4.0)§ 3.4 (2.8, 4.1)§ 2.9 (2.1, 3.7)§ 
Waist circumference, cm 10.9 (9.3, 12.5)§ 11.1 (9.2, 12.9)§ 9.8 (7.5, 12.0)§ 
Fasting glucose, mmol/l 2.2 (1.2, 3.2)§ 2.1 (1.0, 3.2)§ 1.7 (0.8, 2.7)§ 
HbA1c, mmol/mol* 9 (4, 15) 7 (−4, 18) 
HbA1c, %* 0.9 (0.3, 1.4)‡ 0.6 (−0.3, 1.6) 
HDL cholesterol, mmol/l*
 −0.04 (−0.12, 0.05) −0.17 (−0.32, −0.01)† 
Triglycerides, mmol/l* 0.23 (0.05, 0.41)† 0.09 (−0.05, 0.22) 
Systolic BP, mmHg 7.8 (−0.2, 15.7) 5.9 (−1.5, 13.2) 3.9 (−2.7, 10.6) 
Diastolic BP, mmHg 7.8 (3.2, 12.4)‡ 6.1 (2.6, 9.6)‡ 4.3 (0.2, 8.4)† 
Data are mean differences (95% confidence intervals): baseline values minus those at follow-up. 
*Not measured at 5 months; †P < 0.05; ‡P < 0.01; §P < 0.001.
Table 3 Comparison of baseline characteristics and weight loss in responders (FPG < 7mmol/l at 8 weeks) and 
non-responders (FPG ≥ 7mmol/l at 8 weeks)  
Responders 
(N = 15) 
Non-responders 
(N = 10) 
Difference 
(95% CI) 
P-
value 
Baseline characteristics 
Age, years 48.3 (11.3) 47.5 (9.2) 0.8 (−8.1, 9.6) 0.86 
Men, % 80 20 
Women, % 46.7 53.3 1.7 (0.9, 3.2)* 0.10 
Duration diabetes, years 2.9 (2.2) 3.2 (2.1) −0.3 (−2.1, 1.6) 0.76 
Weight, kg 101.0 (23.1) 94.8 (16.7) 6.2 (−11.4, 23.8) 0.47 
BMI, kg/m
2
 35.1 (6.7) 32.8 (4.9) 2.3 (−2.8, 7.4) 0.36 
Waist circumference, cm 107.5 (16.4) 102.2 (13.3) 5.3 (−7.7, 18.2) 0.41 
Fasting plasma glucose, mmol/l 9.3 (2.4) 9.1 (1.7) 0.2 (−1.6, 2.1) 0.79 
HbA1c, mmol/mol 63 (19) 70 (19) −8 (−23, 8) 0.34 
HbA1c, % 7.9 (1.7) 8.6 (1.7) −0.7 (−2.1, 0.8) 0.34 
Insulin 30-min increment, 
pmol/l† 57.5 (46.1,92.2) 26.5 (21.5,39.5) 31.0 (8.4, 63.2) 
0.01 
HDL, mmol/l 0.76 (0.05) 0.91 (0.10) 
−0.14 (−0.36, 
0.08) 
0.49 
Triglycerides, mmol/l 1.22 (0.11) 1.03 (0.14) 0.19 (−0.17, 0.56) 0.27 
Alanine aminotransferase, U/l 21.9 (13.7) 18.9 (7.4) 3.1 (−6.8, 12.9) 0.77 
Systolic BP, mmHg 130.2 (13.5) 127.5 (14.5) 2.8 (−9.2, 14.7) 0.86 
Weight loss at 8 weeks 
Weight loss, kg 10.7 (5.3) 9.2 (3.8) 1.5 (−2.5, 5.5) 0.18 
Per cent change from baseline 10.1 (3.6) 9.4 (2.3) 0.7 (−2.0, 3.3) 0.32 
Category of weight loss, % 
< 10 kg 42.9 57.1 
≥ 10 kg 81.8 18.2 1.9 (1.0, 3.7)‡ 0.048 
Values are means (SD) unless stated otherwise. 
*Risk ratio: men vs. women. †Values are median (IQR). ‡Risk ratio ≥ 10 kg vs. < 10 kg.
Table 4 Insulinogenic index in responders and non-responders at the three time points of the meal tests 
Responders (N = 15) Non-responders (N = 10)† Difference (95% CI) P-value 
Baseline 576.6 (291.3) 120.9 (46.1) 455.67 (−218.45, 1129.79) 0.174 
8 weeks 266.1 (67.5) 115.2 (36.2) 150.88 (−58.12, 359.88) 0.147 
8 months 421.7 (106.4) 99.9 (20.3) 321.72 (32.49, 610.94) 0.031 
Values are given as means (SE) unless stated otherwise. 
Insulinogenic index = 30-min increment in insulin (pmol/l) divided by 30-min increment in glucose (mmol/l). 
†At 8 months, one participant was lost to follow-up and there were nine participants in this category. 


